NEW YORK (GenomeWeb News) – Applied Biosystems said today that it has signed a non-exclusive reseller agreement with BioTrove to offer combined mass spectrometry technologies.
The firm will sell to drug discovery researchers an end-to-end workflow offering that includes mass spec instruments from ABI and its joint-venture partner, MDS Analytical Technologies, and BioTrove’s RapidFire Mass Spectrometry Sample Preparation System. The mass spec instruments included in the agreement are the API 5000 and API 4000 triple quadrupole, and the 4000 QTrap.
The firms also will team up to provide a single service plan, said ABI. The service plan will include application support, instrument maintenance, and ABI’s Smart Monitoring Service.
BioTrove’s RapidFire System can conduct automated sample prep at a rate of six to eight seconds per sample, which the firms said compares to several minutes per sample for HPLC systems. ABI said that the RapidFire System is currently used by 11 of the world’s 15 largest pharmaceutical firms.
"The complete solution of RapidFire and Applied Biosystems/MDS Analytical Technologies instrument systems makes it easier for pharmaceutical companies to adopt high-throughput mass spectrometry technology into critical areas of drug discovery research that may not have had access to this technology," Tamara Bond, senior director of ABI’s pharmaceutical business, said in a statement.
Last year, ABI and BioTrove signed an alliance to combine ABI’s genotyping tools with BioTrove’s OpenArray platform.